Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Withdrawn 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1

Interventions

Cyclophosphamide 6fludarabine phosphate 5Cytarabine 4Peripheral Blood Stem Cell Transplantation 3Methotrexate 3Doxorubicin 3venetoclax 2navitoclax 2merphos 2fludarabine 2Whole-Body Irradiation 2Vincristine 2Pentetic Acid 2Mycophenolic Acid 2Filgrastim 2Etoposide 2Daunorubicin 2Biopsy 2Asparaginase 2sargramostim 1romidepsin 1prednylidene 1pegaspargase 1nelarabine 1lentiviral minigene vaccine of COVID-19 coronavirus 1hydrocortisone hemisuccinate 1ethanolamine oleate 1duvelisib 1dexamethasone acetate 1dexamethasone 21-phosphate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Precursor T-Cell Lymphoblastic Leukemia-Lymphoma × navitoclax × Clear all
NCT05740449 2024-06-21

HEM-iSMART A

Princess Maxima Center for Pediatric Oncology

Phase 1/2 Withdrawn
LymphoidOther hematologic neoplasm

Leukemia, Recurrence, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT06210750 2024-05-17

Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)

National Cancer Institute (NCI)

Phase 2 Withdrawn
LymphoidOther hematologic neoplasm

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡